Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

ClinicalTrials.gov ID: NCT00133991

Public ClinicalTrials.gov record NCT00133991. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 19, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma

Study identification

NCT ID
NCT00133991
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Enrollment
23 participants

Conditions and interventions

Interventions

  • Cyclophosphamide Drug
  • Cytarabine Drug
  • Filgrastim Biological
  • Hydrocortisone Drug
  • Leucovorin Drug
  • Methotrexate Drug
  • Prednisone Drug
  • Rituximab Biological
  • Vincristine Drug

Drug · Biological

Eligibility (public fields only)

Age range
30 Years to 120 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2005
Primary completion
Jul 31, 2011
Completion
Jul 31, 2013
Last update posted
Sep 16, 2018

2005 – 2013

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231-2410 —
Drexel University College of Medicine - Center City Hahnemann Campus Philadelphia Pennsylvania 19102 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00133991, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 16, 2018 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00133991 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →